Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6738 plus durvalumab in refractory biliary tract cancer after immunotherapy failure
KCT0004723Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceralasertib, durvalumab in biliary cancer, sponsored by AstraZeneca. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
ceralasertibdurvalumab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on KCT0004723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004723.